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Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is
increasingly used in clinical microbiological laboratories to identify bacteria and fungi at a species
level and to subtype them. The cfiA gene encoding the unique carbapenemases found in
Bacteroides is restricted to division II Bacteroides fragilis strains. The aim of this study was to
evaluate whether MALDI-TOF MS is suitable for differentiating B. fragilis strains which harbour the
cfiA gene from those that do not. A well-defined collection of 40 B. fragilis isolates with known
imipenem MICs (0.062–.32 mg l”1) were selected for this study. Twelve B. fragilis strains with
known cfiA status, including NCTC 9343 (division I) and TAL3636 (division II), were measured by
means of microflex LT MALDI-TOF MS and well-defined differences in mass spectra between the
cfiA-positive and cfiA-negative strains were found in the interval 4000–5500 Da. A further
28 strains were selected for the blind measurements: 9 cfiA-positive clinical isolates with
different imipenem MICs ranging between 0.06 and .32 mg l”1 (different expressions of the
metallo-b-lactamase gene) were clearly separated from the 19 cfiA-negative isolates. The
presence or absence of the selected peaks in all tested strains clearly differentiated the strains
belonging to B. fragilis division I (cfiA-negative) or division II (cfiA-positive). These results suggest
a realistic method for differentiating division II B. fragilis strains (harbouring the cfiA gene) and to
determine them at a species level at the same time. Although not all cfiA-positive B. fragilis strains
are resistant to carbapenems, they all have the possibility of becoming resistant to this group of
antibiotics by acquisition of an appropriate IS element for full expression of the cfiA gene, leading
to possible treatment failure.
INTRODUCTION
Bacteroides fragilis, one of the most important species in the
Bacteroides genus, is the leading anaerobic pathogen in
human monobacterial or polymicrobial infections (Aldridge
et al., 2003). It is part of the Cytophaga–Flavobacterium–
Bacteroides group (Gherna & Woese, 1992), which is distant
in evolutionary terms from most other bacteria of medical
interest. The genus Bacteroides appears to be one that evolves
rather rapidly (Shah, 1990) and molecular genetic methods
have led to novel, highly related species being included in the
genus recently; however, some other species have been
removed (Song et al., 2004, 2005; Sakamoto & Benno, 2006).
Members of the Bacteroides genus, including B. fragilis, often
exhibit resistance to different drugs, such as b-lactam and
b-lactamase inhibitor combinations, clindamycin, fourth-
generation fluoroquinolones, metronidazole or carbape-
nems, used for treatment of infections involving anaerobes.
Their correct species identification may be necessary because
the resistance to different anti-anaerobic drugs may differ
according to the species (Snydman et al., 2007). Matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) has been shown to
constitute a useful and simple method for the rapid
identification of different human pathogenic bacteria,
including Bacteroides strains, based on the spectrum of
constantly expressed high-abundance proteins such as
ribosomal proteins or to a less extent the highly prevalent
Abbreviations: IS, insertion sequence; MALDI-TOF, matrix-assisted laser
desorption/ionization time-of-flight; MSP, main spectra.
A supplementary table showing the characteristic peaks of the cfiA-
positive and cfiA-negative B. fragilis strains is available with the online
version of this paper.
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housekeeping proteins (Bizzini & Greub, 2010; Nagy et al.,
2009). Only a few studies have as yet been performed with
this method to prove the presence of resistance mechanisms.
Cell wall and proteome-related structural alterations
reflected in the mass spectra of meticillin-resistant Staphy-
lococcus aureus as compared with meticillin-sensitive strains
were described some years ago (Edwards-Jones et al., 2000),
and a ‘proteome shift’ in Candida albicans that corresponds
to its fluconazole MIC measured by conventional methods
was reported recently (Marinach et al., 2009).
Despite the fact that B. fragilis isolates appear phenotypically
homogeneous, DNA–DNA hybridization experiments have
proven that they may be divided into two DNA homology
groups, I and II, which display 65–70% intergroup and 80–
90% intragroup similarity (Johnson, 1978; Johnson & Ault,
1978; Gutacker et al., 2000). The two divisions of B. fragilis
can be distinguished by ribotyping and analysis of the
fragment patterns generated by arbitrarily primed PCR or
multilocus enzyme electrophoresis (Gutacker at al., 2000,
2002; Podglajen et al., 1995; Ruimy et al., 1996). Two
chromosomal cephalosporinase genes have been described in
B. fragilis. The cepA gene encodes a class 2e cephalosporinase
(Parker & Smith, 1993). The production of CepA leads to
resistance to most b-lactam antibiotics, with the exception of
the cephamycins, the carbapenems and the b-lactamase
inhibitor combinations. The other chromosomal b-lactamase
gene is cfiA (also known as ccrA), which expresses a class B
metallo-b-lactamase that confers resistance in B. fragilis to all
b-lactam antibiotics, including carbapenems (Rasmussen
et al., 1990). For the expression of this gene, special insertion
sequence (IS) elements are needed immediately upstream of
the cfiA gene to act as a promoter (Podglajen et al., 1994). The
presence of the cfiA gene on the chromosome of randomly
selected B. fragilis clinical isolates is muchmore frequent (2.4–
6.9%) than carbapenem resistance (~1%) detected during
resistance surveillances (Nagy, 2010). A silent cfiA gene has
been shown to be expressed, leading to carbapenem
resistance, if the necessary IS element, present in any other
part of the chromosome, is inserted in the appropriate
upstream region of the gene (Podglajen et al., 1994). The cfiA
gene can be detected only on the chromosome of B. fragilis
strains belonging to division II (Gutacker et al., 2000;
Podglajen et al., 1995).
The aim of the present study was to use MALDI-TOF MS
to distinguish B. fragilis strains which harbour the cfiA gene
from those which do not, thereby providing a possibility
for differentiating B. fragilis strains belonging to divisions I
and II by this method.
METHODS
Isolates. Thirty-eight B. fragilis strains were selected from our strain
collection for this study; they had known imipenem MICs, and had
previously been characterized by PCR and sequencing for the presence
of the cfiA gene and IS elements in the chromosome (Table 1). All these
strains were clinical isolates originating from different resistance
surveillance studies carried out locally or on a European level; some of
them originated from the USA. B. fragilis NCTC 9343 and TAL3636
were used as control strains belonging to division I and II, respectively.
In the second part of the study, the spectra of 145 B. fragilis strains
previously identified by MALDI-TOF MS (Nagy et al., 2009) were re-
evaluated in a search for specific peaks found characteristic of division I
or II of B. fragilis in the first part of the study. All strains were stored in
cryobank vials (Mast Diagnostics) and cultured on Columbia agar base
(Oxoid) supplemented with 5% (v/v) cattle blood, haemin (1 mg l21)
and vitamin K1 (5 mg l
21) for 24–48 h at 37 uC in an anaerobic
chamber (Concept 400; Ruskinn Technology). Imipenem MIC
measurements were carried out using Etest (AB Biodisk).
Detection of the cfiA gene and IS elements. PCR detection of the
cfiA gene and the IS elements upstream of the resistance gene (PCR
mapping) or in other parts of the chromosome was carried out as
previously described (So´ki et al., 2004, 2006).
Sample preparation for MALDI-TOF MS measurement. One
colony of each bacterial strain, which had been subcultured for 24 h
in an anaerobic environment, was transferred into an Eppendorf vial
and carefully suspended in 300 ml bidistilled water. Ethanol (900 ml)
was added to the suspension, and mixed well. For MALDI-TOF MS
analyses the stabilized samples were sent from the Anaerobe Reference
Laboratory in Hungary to the Bruker laboratory in Bremen
(Germany). Further sample preparation was carried out as described
previously (Nagy et al., 2009). In brief, the samples were centrifuged
(13 000 g for 2 min), the supernatants were removed and the pellets
were dried at room temperature and resuspended in 50 ml 70%
aqueous formic acid and 50 ml acetonitrile. After centrifugation
(13 000 g for 2 min), 1 ml of the supernatant was placed onto the
MALDI target plate and dried at room temperature, followed by
adding 2 ml MALDI matrix (saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% acetonitrile/2.5% trifluoroacetic acid).
MALDI-TOF MS measurement. All measurements were performed
on a microflex LT MALDI-TOF mass spectrometer in the linear
positive ion mode, with a laser frequency of 60 Hz. The mass range
was 2000–20 000 Da. For each sample, the sum spectra of 240 single
spectra were acquired, in portions of 40 single spectra from 6 different
positions on a spot. For each sample, at least 20 separate sum spectra
were collected.
Data processing. The mass spectra generated for the analysed
bacteria were identified as derived from B. fragilis strains by using the
MALDI Biotyper 2.0 software and database (version 3.1.1.0., 3740
entries; Bruker Daltonik). Identification was performed with the
standard pattern matching approach as recommended by the
manufacturer, applying log(score) ¢2.0 for species identification.
For the detection of cfiA-positive and cfiA-negative specific peaks,
respectively, mass spectrum sets of well-defined cfiA-positive and
cfiA-negative B. fragilis strains were imported in the ClinProTools 2.2
software (Bruker Daltonik). Spectra were normalized and recalibrated
using the respective functionalities of the software. Subsequently,
group-characteristic peaks and peak shifts were searched for by
careful visual investigation of the spectrum sets. In addition, peak
variations between the two groups were investigated by using the
FlexAnalysis 3.3 software (Bruker Daltonik).
Correlation analysis was performed using the MALDI Biotyper 2.0
software with standard settings (mass range 3000–12 000 Da,
resolution 4, eight intervals, autocorrelation off). Twenty different
profile spectra were used for each strain in this analysis. Principle
component analysis was carried out with the respective ClinProTools
2.2 algorithm for normalized data.
Main spectra (MSP) for the creation of a cfiA-positive/cfiA-negative
differentiating library were calculated from six strains each of which
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had previously been demonstrated to belong to division II or division
I. This resulted in a library containing two reference entries: one
specific for cfiA-positive and one for cfiA-negative B. fragilis strains.
MSP calculations relating to the cfiA-positive/cfiA-negative library
and pattern matching against the created library were performed by
using MALDI Biotyper 2.0 with standard settings.
RESULTS
Twelve B. fragilis strains (six cfiA-positive and six cfiA-
negative) were selected for the first measurement. Besides
the two control strains (NCTC 9343, cfiA-negative strain;
and TAL3636, cfiA-positive strain), ten clinical isolates were
Table 1. B. fragilis strains tested in previous studies for the presence of the cfiA gene and selected for the MALDI-TOF MS study
Number B. fragilis Origin Division defined
by MALDI-TOF
MS profile
PCR
detection of
cfiA gene
IS element(s)* Imipenem
MIC
(mg l”1)D
Reference
1 TAL3636 USA II + IS942 .32 Rasmussen et al.
(1990)
2 NCTC 9343 UK I 2 2 0.062 Cerden˜o-Ta´rraga
et al. (2005)
3 1672 USA II + IS1186, (IS4351) .32 So´ki et al. (2004)
4 R19811 UK II + IS614B 32 Terhes et al. (2007)
5 O21 Sweden II + IS1186, (IS4351) .32 Nagy et al. (2011)
6 6712 USA II + IS612B .32 So´ki et al. (2004)
7 2944 USA II + IS614B .32 So´ki et al. (2004)
8 CZE60 Czech II + 2 16 So´ki et al. (2006)
9 7979 Hungary II + 2 16 This study
10 16997 Hungary II + 2 16 This study
11 21216 Hungary II + 2 8 So´ki et al. (2004)
12 BF8 France II + (IS1186, IS4351) 1 Podglajen et al.
(1994)
13 22 Hungary II + 2 0.062 So´ki et al. (2000)
14 25877 Hungary II + 2 0.125 This study
15 20384 Hungary II + 2 0.125 This study
16 72 Hungary II + 2 0.25 So´ki et al. (2000)
17 59775 Hungary I 2 NT 0.25 This study
18 15470 Hungary I 2 NT 0.25 This study
19 15467 Hungary I 2 NT 1 This study
20 15361 Hungary I 2 NT 0.5 This study
21 72232 Hungary I 2 NT 0.5 This study
22 17797 Hungary I 2 NT 0.25 This study
23 5269 Hungary I 2 NT 4 This study
24 P35 Hungary I 2 NT 0.25 This study
25 8887 Hungary I 2 NT 2 Nagy et al. (2011)
26 13859 Hungary I 2 NT 0.25 Nagy et al. (2011)
27 12790 Hungary I 2 NT 1 Nagy et al. (2011)
28 14850 Hungary I 2 NT 0.25 Nagy et al. (2011)
29 14285 Hungary I 2 NT 0.5 Nagy et al. (2011)
30 14176 Hungary I 2 NT 1 Nagy et al. (2011)
31 AN1040 Sweden I 2 NT 0.25 Nagy et al. (2011)
32 T1 Turkey I 2 NT ,0.125 Nagy et al. (2011)
33 T2 Turkey I 2 NT ,0.125 Nagy et al. (2011)
34 G2 Greece I 2 NT 0.5 Nagy et al. (2011)
35 DE1 Germany I 2 NT ,0.125 Nagy et al. (2011)
36 DE2 Germany I 2 NT ,0.125 Nagy et al. (2011)
37 53156 Finland I 2 NT ,0.125 Nagy et al. (2011)
38 NL8 The Netherlands I 2 NT 0.125 Nagy et al. (2011)
39 NL9 The Netherlands I 2 NT ,0.125 Nagy et al. (2011)
40 638R USA I 2 NT 0.5 So´ki et al. (2000)
*IS elements upstream of the cfiA genes are indicated. IS elements found by IS PCR, but not upstream of the cfiA genes, are shown in parentheses.
NT, Not tested.
DBreakpoints for imipenem: susceptible, ¡4 mg l21; resistant, ¢16 mg l21.
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involved. All isolates had previously been identified as B.
fragilis and investigated in detail for the presence of the cfiA
gene, the IS elements and the level of imipenem resistance.
After the routine measurements, microflex LT MALDI-TOF
MS differences were looked for. Figs 1 and 2 show
characteristic differences in the interval 4000–5500 Da,
visualized by the gel/stack view in ClinProTools with
Flexanalysis software. A further 28 strains were selected for
the blind measurements: 9 further cfiA-positive clinical
isolates with different imipenemMICs (different expressions
of the metallo-b-lactamase gene) ranging between 0.06 and
.32 mg l21, and 19 cfiA-negative isolates with imipenem
MICs between ,0.125 and 0.5 mg l21, previously selected
from our culture collection and tested for possible silent
carriage of the gene. During the two measurements, the
presence or absence of the selected peaks in theMALDI-TOF
spectrum between 4600 and 10 600 allowed a 100%
distinction between the strains belonging to B. fragilis
division I (cfiA-negative) or division II (cfiA-positive)
(Supplementary Table S1 in JMM Online).
In a previous collaborative study (Nagy et al., 2009), 277
clinical Bacteroides isolates were identified at a species level
by MALDI-TOF MS. From among these, the spectra of 145
B. fragilis isolates with a high log(score) (¢2.5) were re-
evaluated and the characteristic peaks defined earlier for
division II were looked for. Nine isolates (6.2%) belonged to
B. fragilis division II (Table 2). All nine isolates were cfiA-
positive, with imipenem MICs varying between ,0.125 and
.32 mg l21. Even isolates with silent carriage of the cfiA
gene were detected by this method. Two of the characteristic
peaks (4826 and 9649 Da) were found in all nine strains and
a third one (9375 Da) was present in eight of the nine strains.
For further statistical analysis, composite correlation index
analysis was performed with profile spectra from the initial six
cfiA-positive strains and six cfiA-negative strains. The correla-
tion between the different cfiA-positive strains was found to
be 0.84–0.97, while that in the cfiA-negative group was 0.86–
0.98. In contrast with these high correlations within the two
groups, the correlation indices calculated for strains from
different groups (i.e. cfiA-positive vs cfiA-negative) were only
0.45–0.62, confirming the clear spectral difference between
strains harbouring or not the cfiA gene. Principle component
analysis performed with the initial 12 B. fragilis strains also
resulted in a clear separation of two clusters, consisting of
cfiA-positive and cfiA-negative strains, respectively.
To investigate the possibility of predicting cfiA-negative and
cfiA-positive B. fragilis strains with the MALDI Biotyper
pattern matching approach, a small library containing only
two reference spectra (MSP), one specific for cfiA-negative
and one for cfiA-positive strains, was calculated from the
Fig. 1. Characteristic differences in the MS peaks in the interval 4000–5500 Da between the strains harbouring the cfiA gene
and those which do not, visualized by the gel/stack view. Peak shifts can be observed from cfiA-negative to cfiA-positive strains:
4711 DaA4688 Da, 4817 DaA4826 Da, 5017 DaA5002 Da, 5204 DaA5189 Da and 5268 DaA5282 Da.
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B. fragilis division I and division II strains from the first test
set. This library was challenged with spectra of the 9 further
cfiA-positive and 19 randomly selected cfiA-negative strains
(three spectra per strain). In all cases, the MALDI Biotyper
software classified the B. fragilis strains correctly, indicating
the suitability of such an approach for the classification of
divisions I and II of B. fragilis (data not shown).
DISCUSSION
Since the introduction of MALDI-TOF MS for pure
microbiological applications, it has evolved from an experi-
mental tool to a technology with significant benefit for
routine as well as for scientific investigations. It is currently
applied especially in clinical microbiology for the identifica-
tion of various bacteria or fungi at a species or subspecies level
Fig. 2. Example of the clear differences in the MS peaks in the interval 4650–4850 Da between the cfiA-positive and -negative
strains. (a) Visualized by the gel/stack view. (b) Visualized by the mass spectra. Peaks are shifted from 4711 Da and 4817 Da
(cfiA-negative) to 4688 Da and 4826 Da (cfiA-positive), respectively.
Table 2. B. fragilis strains identified at a species level in a previous study by MALDI-TOF MS and selected for the current study
according to the presence of the characteristic peaks for division II
B. fragilis Characteristic MS peaks for division II* cfiA (PCR) IS upstream of the gene Imipenem MIC (mg l”1)
A-20 4826, 9375, 9649 + 2 ,0.125
Ba-16 4826, 9375, 9649 + 2 ,0.125
Bb-15 4826, 7321, 9375, 9649 + 2 2
Bb-32 4826, 7321, 9375, 9649 + 2 2
Be-3 4826, 7321, 9375, 9649 + 2 0.5
Bm-2 4826, 7321, 9375, 9649, 4688, 5002, 5189 + 2 1
Fr-19 4826, 7321, 9649 + 2 1
Nl-3 4688, 4826, 5002, 5189, 7321, 9375, 9649 + IS614-like .32
Nl-1 4688, 4826, 5002, 5189, 7321, 9375, 9649 + 2 2
*Characteristic peaks found in all nine strains (4826 and 9649 Da) or in eight of the nine strains (9375 Da) are in bold.
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after a positive culture, as it requires very limited time for
sample preparation and measurement (Bizzini & Greub,
2010; Nagy et al., 2009; Murray, 2010). At present, very little
information is available on the use of this technique for the
direct identification of pathogens from clinical samples with
or without preculturing (Drancourt, 2010) or for determina-
tion of the antibiotic resistance of isolated pathogens
(Edwards-Jones et al., 2000; Marinach et al., 2009).
The results of the present study demonstrate the
applicability of MALDI-TOF MS for both the subtyping
and the detection of the presence of an important
resistance mechanism of B. fragilis, a frequently isolated
anaerobic pathogen. With the successful differentiation of
B. fragilis strains belonging to divisions I and II at the
same time as their identification at a species level by
MALDI-TOF MS, it is possible to predict the presence
of an important resistance phenotype with respect to
carbapenems, one of the most important group of
antimicrobials used in treating mixed infections. The
carbapenem resistance of B. fragilis is due to a species-
specific metallo-b-lactamase, which is encoded by the cfiA
(ccrA) gene of the organism. Almost 100% of the
carbapenem-resistant Bacteroides strains are cfiA-positive
B. fragilis isolates. The recognition that B. fragilis can be
subgrouped into two divisions dates back to the late
1970s, when Johnson & Ault (1978) demonstrated
differences in DNA–DNA homology rates not only
between the known Bacteroides species, but also between
two groups of strains of B. fragilis subsp. fragilis (now
B. fragilis). Cloning and sequencing of the metallo-b-
lactamase gene allowed screening of the B. fragilis
population, which demonstrated that there are strains
that are not imipenem-resistant despite harbouring the
cfiA resistance gene; in the case of strains with high-level
resistances to imipenem, an activator IS element is needed
to insert upstream of the cfiA gene in normal flora, and
clinical or experimental isolates (Podglajen et al., 1994;
So´ki et al., 2000, 2004). Further investigations revealed
that the cfiA-positive strains belong only to division II,
and the cfiA-positive and -negative strains can be
differentiated by various molecular typing methods
(Gutacker et al., 2000; Podglajen et al., 1995; Terhes
et al., 2007). The finding that the genome and the most
important housekeeping genes and rRNA gene sequences
differentiate the two divisions reflects the fact that the
differences emerged during the early evolution of the
species. Through the use of MALDI-TOF MS to identify
ribosomal proteins in the present study, the two divisions
of B. fragilis can be differentiated in a relatively cheap and
up-to-date manner. During the time of publication of our
results, Wybo et al. (2011) using MALDI Biotyper showed
through preparing a dendrogram or using the composite
correlation index the clear separation of cfiA-positive
(n541) and cfiA-negative (n5207) B. fragilis strains from
their collection.
As concerns the cfiA-positive B. fragilis isolates selected for
our study, the expression of their resistance and genetic
background had previously been investigated in detail: (i)
phenotypically resistant strains (MIC¢16 mg l21) with IS
elements in the upstream region of the cfiA genes; (ii)
phenotypically resistant strains (MIC¢16 mg l21) or with
elevated imipenem MICs (1 and 8 mg l21), but without IS
elements upstream of the cfiA genes; and (iii) phenotypi-
cally fully susceptible strains (MIC¡0.25 mg l21) without
IS elements upstream of the cfiA genes. These three groups
of strains could not be distinguished by MALDI-TOF MS,
which confirms that more significant genetic changes than
merely the movement of IS elements in the genome are
responsible for the differences in the MS spectrum. The
second group of cfiA-positive isolates mentioned above has
not yet been sufficiently well characterized as regards the
exact expression mechanisms, but our investigations demon-
strated that these strains are heterogeneously resistant to
carbapenems andmay utilize a weak self-promoter of the cfiA
genes (Rasmussen et al., 1990; Podglajen et al., 1994; our
unpublished results).
Recent results have demonstrated that the cfiA genes in
some B. fragilis strains belonging to division II are located
in a contiguous sequence with other unrelated genes that
replace a portion of a chromosomal segment in the
sequenced genome of B. fragilis NCTC 9343 belonging to
division I (Thompson & Malamy, 1990). However, it has
been shown that the cfiA genes may be present in multiple
copies in the genomes in some strains (Podglajen et al.,
1994; our unpublished results). Our explanation for these
phenomena is that the chromosomal segment carrying the
cfiA gene and the accompanying genes forms a genetic
element which can be mobile within a strain, but whose
transfer between the two divisions is restricted.
Although not all cfiA-positive B. fragilis strains are resistant
to carbapenems, they all have the potential to become
resistant to this important group of antibiotics by
acquisition of an appropriate IS element for full expression
of the cfiA gene. Confirmation by MALDI-TOF MS of the
separation of the B. fragilis genomic divisions at the same
time as the species determination could be useful in clinical
microbiology laboratories for the detection of resistance to
this important antibiotic in B. fragilis.
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